QR код

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practi...

Повний опис

Збережено в:
Автори: Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Формат: Artigo
Мова:Inglês
Опубліковано: Nature Portfolio 2024-10-01
Серія:npj Breast Cancer
Онлайн доступ:https://doi.org/10.1038/s41523-024-00699-3
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси